
NASDAQHealthcareMedical - Devices
ข้อมูลล่าสุด
US$9.17
+US$0.17 · +1.89%
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
ราคาปิดก่อนหน้า
US$9.17
+US$0.17 · +1.89%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
ช่วงราคารายวัน
ปัจจุบัน US$9.17
ช่วง 52 สัปดาห์
ปัจจุบัน US$9.17
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
64
ต่ำกว่ามูลค่า
ความเชื่อมั่น
68
เชิงบวก
ความเสี่ยง
57
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
42
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
ช่วงราคารายวัน
ปัจจุบัน US$9.17
ช่วง 52 สัปดาห์
ปัจจุบัน US$9.17
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 822.31M USD | 799.49M USD | 746.64M USD | 460.71M USD | 464.48M USD |
| ต้นทุนสินค้าขาย | 270.61M USD | 253.61M USD | 260.37M USD | 123.54M USD | 114.91M USD |
| กำไรขั้นต้น | 551.71M USD | 545.89M USD | 486.27M USD | 337.17M USD | 349.57M USD |
| การวิจัยและพัฒนา | 57.11M USD | 73.64M USD | 80.23M USD | 49.07M USD | 49.62M USD |
| การขาย ทั่วไป และธุรการ | 456.39M USD | 532.53M USD | 530.4M USD | 308.78M USD | 290.67M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 620.18M USD | 630.5M USD | 625.38M USD | 350.44M USD | 357.88M USD |
| ดอกเบี้ยจ่าย | 17.49M USD | 29.63M USD | 8.63M USD | 1.29M USD | 1.84M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 83.26M USD | 75.96M USD | 60.56M USD | 32.08M USD | 33.1M USD |
| รายได้จากการดำเนินงาน | −68.47M USD | −84.62M USD | −139.11M USD | −13.27M USD | −8.32M USD |
| รายได้สุทธิ | −92.19M USD | −126M USD | −151.4M USD | −19.75M USD | −38.38M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 10 ต.ค. 2569.
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$13.40
โอกาสปรับขึ้น 46.13%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI11.41M0.00%2.3T USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM9.48M0.01%78.27B USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF4.43M0.00%95.4B USD0.05%US$235+0.80%
iShares Russell 2000 Value ETFIWN3.25M0.02%13.85B USD0.24%US$210.87-0.04%
Vanguard Russell 2000 ETFVTWO2.19M0.01%18B USD0.06%US$112.66+0.50%
Dimensional - US Small Cap ETFDFAS1.93M0.01%33.87B USD0.31%US$78.35+0.32%
Schwab U.S. Small-Cap ETFSCHA1.91M0.01%21.73B USD0.03%US$32.79+0.40%
iShares U.S. Medical Devices ETFIHI1.81M0.05%3.55B USD0.37%US$51.74+1.25%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
Vanguard Russell 2000 ETFVTWO
Dimensional - US Small Cap ETFDFAS
Schwab U.S. Small-Cap ETFSCHA
iShares U.S. Medical Devices ETFIHIเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน